621 related articles for article (PubMed ID: 22436957)
1. Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial.
Tan J; Wu W; Xu X; Liao L; Zheng F; Messinger S; Sun X; Chen J; Yang S; Cai J; Gao X; Pileggi A; Ricordi C
JAMA; 2012 Mar; 307(11):1169-77. PubMed ID: 22436957
[TBL] [Abstract][Full Text] [Related]
2. Prospective randomized controlled trial of rabbit antithymocyte globulin compared with IL-2 receptor antagonist induction therapy in kidney transplantation.
Pilch NA; Taber DJ; Moussa O; Thomas B; Denmark S; Meadows HB; McGillicuddy JW; Srinivas TR; Baliga PK; Chavin KD
Ann Surg; 2014 May; 259(5):888-93. PubMed ID: 24513787
[TBL] [Abstract][Full Text] [Related]
3. Allogeneic mesenchymal stem cell as induction therapy to prevent both delayed graft function and acute rejection in deceased donor renal transplantation: study protocol for a randomized controlled trial.
Sun Q; Hong L; Huang Z; Na N; Hua X; Peng Y; Zhao M; Cao R; Sun Q
Trials; 2017 Nov; 18(1):545. PubMed ID: 29145879
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy Outcomes 3 Years After Switching to Belatacept From a Calcineurin Inhibitor in Kidney Transplant Recipients: Results From a Phase 2 Randomized Trial.
Grinyó JM; Del Carmen Rial M; Alberu J; Steinberg SM; Manfro RC; Nainan G; Vincenti F; Jones-Burton C; Kamar N
Am J Kidney Dis; 2017 May; 69(5):587-594. PubMed ID: 27889299
[TBL] [Abstract][Full Text] [Related]
5. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
6. Infusion of third-party mesenchymal stromal cells after kidney transplantation: a phase I-II, open-label, clinical study.
Erpicum P; Weekers L; Detry O; Bonvoisin C; Delbouille MH; Grégoire C; Baudoux E; Briquet A; Lechanteur C; Maggipinto G; Somja J; Pottel H; Baron F; Jouret F; Beguin Y
Kidney Int; 2019 Mar; 95(3):693-707. PubMed ID: 30528263
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 receptor antibody reduces rejection rates and graft loss in live-donor kidney transplant recipients.
Lim WH; Chang SH; Chadban SJ; Campbell SB; Dent H; Russ GR; McDonald SP
Transplantation; 2009 Nov; 88(10):1208-13. PubMed ID: 19935375
[TBL] [Abstract][Full Text] [Related]
8. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation.
Vincenti F; Ramos E; Brattstrom C; Cho S; Ekberg H; Grinyo J; Johnson R; Kuypers D; Stuart F; Khanna A; Navarro M; Nashan B
Transplantation; 2001 May; 71(9):1282-7. PubMed ID: 11397963
[TBL] [Abstract][Full Text] [Related]
9. Donor-derived mesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study.
Peng Y; Ke M; Xu L; Liu L; Chen X; Xia W; Li X; Chen Z; Ma J; Liao D; Li G; Fang J; Pan G; Xiang AP
Transplantation; 2013 Jan; 95(1):161-8. PubMed ID: 23263506
[TBL] [Abstract][Full Text] [Related]
10. Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study.
Budde K; Rath T; Sommerer C; Haller H; Reinke P; Witzke O; Suwelack B; Baeumer D; May C; Porstner M; Arns W
Clin Nephrol; 2015 Jan; 83(1):11-21. PubMed ID: 25512099
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
Sampaio MS; Kadiyala A; Gill J; Bunnapradist S
Transplantation; 2009 Oct; 88(7):904-10. PubMed ID: 19935462
[TBL] [Abstract][Full Text] [Related]
12. Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation.
Perico N; Casiraghi F; Gotti E; Introna M; Todeschini M; Cavinato RA; Capelli C; Rambaldi A; Cassis P; Rizzo P; Cortinovis M; Noris M; Remuzzi G
Transpl Int; 2013 Sep; 26(9):867-78. PubMed ID: 23738760
[TBL] [Abstract][Full Text] [Related]
13. Low-dose tacrolimus combined with donor-derived mesenchymal stem cells after renal transplantation: a prospective, non-randomized study.
Pan GH; Chen Z; Xu L; Zhu JH; Xiang P; Ma JJ; Peng YW; Li GH; Chen XY; Fang JL; Guo YH; Zhang L; Liu LS
Oncotarget; 2016 Mar; 7(11):12089-101. PubMed ID: 26933811
[TBL] [Abstract][Full Text] [Related]
14. Safety of allogeneic bone marrow derived mesenchymal stromal cell therapy in renal transplant recipients: the neptune study.
Reinders ME; Dreyer GJ; Bank JR; Roelofs H; Heidt S; Roelen DL; Zandvliet ML; Huurman VA; Fibbe WE; van Kooten C; Claas FH; Rabelink TJ; de Fijter JW
J Transl Med; 2015 Nov; 13():344. PubMed ID: 26537851
[TBL] [Abstract][Full Text] [Related]
15. Autologous bone marrow derived mesenchymal stromal cell therapy in combination with everolimus to preserve renal structure and function in renal transplant recipients.
Reinders ME; Bank JR; Dreyer GJ; Roelofs H; Heidt S; Roelen DL; Al Huurman V; Lindeman J; van Kooten C; Claas FH; Fibbe WE; Rabelink TJ; de Fijter JW
J Transl Med; 2014 Dec; 12():331. PubMed ID: 25491391
[TBL] [Abstract][Full Text] [Related]
16. Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers.
Opelz G; Morath C; Süsal C; Tran TH; Zeier M; Döhler B
Transplantation; 2015 Feb; 99(2):400-4. PubMed ID: 25050471
[TBL] [Abstract][Full Text] [Related]
17. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
18. Influence of maintenance steroids on the outcomes in deceased-donor kidney transplant recipients exposed to prolonged pretransplantation dialysis.
Sureshkumar KK; Hussain SM; Thai NL; Marcus RJ
Transplant Proc; 2013; 45(1):99-101. PubMed ID: 23375281
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial.
Sun Q; Huang Z; Han F; Zhao M; Cao R; Zhao D; Hong L; Na N; Li H; Miao B; Hu J; Meng F; Peng Y; Sun Q
J Transl Med; 2018 Mar; 16(1):52. PubMed ID: 29514693
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
